1,720,967 research outputs found
Clinical utility of adjuvant growth hormone in the treatment of patient with PCO undergoing IVF
No full textDifferent effects of transdermal 17 beta-estradiol administration in postmenopausal women with normal and low bone density
No full text
L’ endometrio umano sintetizza una nuova famiglia di fattori di crescita: follistatina, inibina e activina
No full textTreatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study.
No full textThe aim of the present study was to assess the effects of the new fluorine pro-drug monofluorophosphate (MFP) in postmenopausal women with vertebral osteopenia and high bone turnover. We enrolled postmenopausal women (PMW, 43-59 years) who had had a natural menopause 2-5 years before the study, had vertebral bone mineral density (BMD) 1 SD over the mean for premenopausal women. Patients were randomly divided into two treatment groups (group 1, 500 mg/day of oral calcium; group 2, MFP at the dose of 20 mg F-equivalents + 600 mg calcium/day) for 2 years (n = 21 in each group). The lumbar vertebral (L2-4) BMD and total body bone mineral (TBBM) were measured by dual-energy X-ray absorptiometry (Lunar DPX, Lunar Corporation, USA). Urinary hydroxyproline excretion (OH-P/Cr), plasma bone Gla protein (BGP) and serum alkaline phosphatase (AP) were assayed. In group 1 the markers of bone turnover and vertebral BMD did not show any significant modification, while TBBM showed a significant (p < 0.05) decrease after 24 months. In group 2 a significant (p < 0.05) decrease in OH-P/Cr (-23.9 +/- 2.0%), and an increase in both BGP (+19.4 +/- 2.6%) and AP (+10.3 +/- 2.6%) levels were observed after 24 months of MFP administration. In this group, both vertebral BMD (+5.01 +/- 0.9%, p < 0.01) and TBBM (+4.0 +/- 0.6%, p < 0.05) showed a significant increase after 24 months. Present results suggest that, in osteopenic PMW, MFP administration induces a significant increase in vertebral BMD without impairment of cortical bone, with a reduction in bone resorption and an increase in bone formation rate
EFFECTS OF CONTINUOUS AND CYCLIC NASAL CALCITONIN ADMINISTRATION IN OVARIECTOMIZED WOMEN
No full text
Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy.
No full textWe evaluated the effects of low-dose ethinylestradiol administration in the prevention of the rapid bone loss that follows ovariectomy in women. After 10-30 days from surgery, patients received either a sole calcium supplementation 500 mg/day (n = 20) or ethinylestradiol 20 micrograms/day in addition to the same daily calcium supplement (n = 21), for 12 months. In the control group, urinary hydroxyproline excretion, serum alkaline phosphatase and plasma bone Gla protein levels presented a substantial (p < 0.05) increase, while radial bone density significantly (p < 0.05) decreased 6 months after surgery. In the ethinylestradiol-treated group, the patterns of biochemical markers indicated that ethinylestradiol can restrain the bone remodelling processes. Radial bone density showed no significant modification during the 12 months' study period. In conclusions, these results demonstrate that the administration of 20 micrograms/day of ethinylestradiol can prevent the rapid bone loss that follows ovariectom
Activin A and inhibin B in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy
No full textActivin A and inhibin B levels were measured, using a tao-site enzyme immunoassay, in extra-embryonic coelomic fluid, amniotic fluid and maternal serum samples retrieved from 23 healthy pregnant women, at 8 (n = 8), 9 (n = 8), and 10 (n = 7) weeks of gestation. Dimeric activin A and inhibin B were measurable in all samples. Median (+/- SEM) activin A concentrations in coelomic fluid (0.98 +/- 0.34 ng/ml) were significantly higher than in maternal serum (0.68 +/- 0.05 ng/ml) and in amniotic fluid (0.09 +/- 0.04 ng/ml) (P < 0.05). Maternal serum activin A levels were significantly higher than amniotic fluid concentrations. Median(+/- SEM) inhibin B concentrations in coelomic fluid (24.32 +/- 6.02 pg/ml) were significantly higher than in maternal serum (5.94 +/- 0.97 pg/ml) and in amniotic fluid (6.31 +/- 1.53 pg/ml) (P < 0.05), while no significant difference between maternal serum levels and amniotic fluid concentrations was found. No significant difference in activin A and inhibin B levels in extra-coelomic fluid, amniotic fluid, and maternal serum throughout the 3 weeks of pregnancy was found. The present study showed that coelomic fluid is an important reservoir of activin A and inhibin B, supporting the hypothesis that the extra-embryonic coelom mag; have a secretory role during the first 11 weeks of gestation. (C) 1998 W. B. Saunders Company Ltd
- …
